Immuneering Corp

CAMBRIDGE, MA · CIK 0001790340 · Biotech · Public

Deep Cyclic Inhibitors targeting MAPK-driven cancers to prevent resistance and adaptation

immuneering.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$77M
3 Form D · Sep 2025
13 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$14,973,755
Private capital raisedForm D · SEC$37,199,807
Private capital raisedForm D · SEC$24,998,919
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2217Oragenics, Inc.—$67M
2218Discidium Biosciences, LLC——
2219KINETIQ THERAPEUTICS LLC——
2220Immuneering Corp—$77M
2221Pheast Therapeutics—$50M
2222Tmunity Therapeutics—$140M
2223Alloy Therapeutics—$147M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 8 related persons
  • Robert CarpenterDirector
  • Peter FeinbergDirector
  • Diana HausmanDirector
  • Laurie KeatingDirector
  • Joseph KekstDirector
  • Andrew PhillipsDirector
  • Thomas SchallDirector
  • Benjamin ZeskindDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.